DTIC (NSC-45388) in malignant melanoma: a perspective.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014226:Triazenes / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D014226:Triazenes; D008130:Lomustine; D003606:Dacarbazine; D002330:Carmustine